Julie L. Tyler - 17 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
SENIOR VICE PRESIDENT
Signature
/s/ Julie L. Tyler by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
17 Feb 2023
Net transactions value
-$94,302
Form type
4
Filing time
22 Feb 2023, 18:20:22 UTC
Previous filing
27 Jul 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +7,920 +23% $0.000000 41,788 17 Feb 2023 Direct F1
transaction ABT Common shares without par value Tax liability $31,061 -291 -0.7% $106.74 41,497 19 Feb 2023 Direct
transaction ABT Common shares without par value Tax liability $36,398 -341 -0.82% $106.74 41,156 21 Feb 2023 Direct
transaction ABT Common shares without par value Sale $26,842 -260 -0.63% $103.24 40,896 22 Feb 2023 Direct
holding ABT Common shares without par value 9,513 17 Feb 2023 Profit Sharing Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +31,236 $0.000000 31,236 17 Feb 2023 Common Shares 31,236 $106.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025 and 10,412 on February 17, 2026.